Protara Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 5, 2025
TARA$2.51+9.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| (a) | There is no information that was required to be disclosed in a report on Form 8-K during the fourth quarter of 2024 but was not reported. |
| On March 3, 2025, our Board of Directors approved an amendment to our ArTara Therapeutics, Inc. Inducement Plan, or the Inducement Plan, to increase the number of shares of common stock, par value $0.001 per share, reserved for issuance under the Inducement Plan by 600,000 shares, to a new total of 1,200,000 shares of common stock. As previously disclosed, the Inducement Plan was adopted by our Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with Rule 5635(c)(4) of the NASDAQ Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals’ bona fide period of non-employment with the Company), as an inducement material to the individuals’ entry into employment with the Company or in connection with a merger or acquisition, to the extent permitted by Rule 5635(c)(3) of the NASDAQ Listing Rules. The foregoing description of the amendment to the Inducement Plan is not intended to be complete and is qualified in its entirety by reference to the amendment, a copy of which is filed as Exhibit 10.36 to this Annual Report on Form 10-K and is incorporated herein by reference. |
| (b) | Insider trading arrangements The following table provides information concerning Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934) adopted in the fourth quarter of 2024 by any director or any executive officer who is subject to the filing requirements of Section 16 of the Securities Exchange Act of 1934. These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). These trading arrangements permit transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table below. These trading arrangements, identified as “Rule 10b5-1 Trading Arrangements”, only permit transactions upon expiration of the applicable mandatory cooling-off period under Rule 10b5-1. |
| Name | Title | Adoption Date | Duration | Aggregate number of shares of common stock to be purchased or sold pursuant to the trading arrangement |
|---|---|---|---|---|
| Jesse Shefferman | President, Chief Executive Officer and Director | December 27, 2024 | March 31, 2025 – March 31, 2026 | 76,501 |
| Jacqueline Zummo | Chief Scientific Operations Officer | December 23, 2024 | March 26, 2025 – December 23, 2025 | 34,668 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.